2023
Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatment
2021
Cholangiocarcinoma
Lasagni A, Strazzabosco M, Guido M, Fabris L, Cadamuro M. Cholangiocarcinoma. 2021, 231-259. DOI: 10.1007/978-3-030-65908-0_14.Peer-Reviewed Original ResearchTypes of cholangiocarcinomaDifferent epithelial cancersLiver transplantationGastrointestinal malignanciesMost patientsSurgical resectionRich tumor microenvironmentCurative treatmentChronic inflammationNegative marginsAggressive tumorsBiliary treeRare cancersRisk factorsCholangiocarcinomaAdvanced stageEpithelial cancersAnatomical locationTumor microenvironmentPatientsDistinct cancersCancerDesmoplastic natureMultimodal approachLaboratory tests
2017
Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expression 2017, 18: 31-50. PMID: 29070148, PMCID: PMC5860940, DOI: 10.3727/105221617x15088670121925.Peer-Reviewed Original ResearchConceptsMajority of patientsPrimary liver cancerCancer-related deathPotential prognostic relevanceDevelopment of metastasesPro-oncogenic pathwaysNovel druggable targetsMechanism of actionCholangiocarcinoma invasivenessMesenchymal-like phenotypeDevastating malignancyCurative treatmentMolecular mechanismsPoor prognosisPrognostic relevancePrimary tumorBiliary epitheliumLiver cancerUseful biomarkerAbnormal activationCCA cell invasionMost carcinomasCCA cellsTumor microenvironmentCholangiocarcinoma
2013
Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.
Cadamuro M, Morton SD, Strazzabosco M, Fabris L. Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. Translational Gastroenterology And Hepatology 2013, 2: 130-144. PMID: 28989865, PMCID: PMC5627657, DOI: 10.3978/j.issn.2224-4778.2013.04.02.Peer-Reviewed Original ResearchTumor reactive stromaReactive stromaTime of diagnosisRegional lymph nodesPotential new treatmentSpecific therapeutic interventionsNew therapeutic strategiesPro-invasive propertiesNumber of carcinomasCurative intentSurgical resectionLymph nodesCurative treatmentAggressive neoplasmPancreatic cancerBreast cancerTumor stromaTherapeutic strategiesCholangiocarcinomaEpidemiological impactTherapeutic chanceTherapeutic interventionsTumor growthNew treatmentsParacrine communication